| Title |
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta‐analysis
|
|---|---|
| Published in |
Cochrane database of systematic reviews, June 2013
|
| DOI | 10.1002/14651858.cd008933.pub2 |
| Pubmed ID | |
| Authors |
Graziella Filippini, Cinzia Del Giovane, Laura Vacchi, Roberto D'Amico, Carlo Di Pietrantonj, Deirdre Beecher, Georgia Salanti |
| Abstract |
Different therapeutic strategies are available for treatment of multiple sclerosis (MS) including immunosuppressants, immunomodulators, and monoclonal antibodies. Their relative effectiveness in the prevention of relapse or disability progression is unclear due to the limited number of direct comparison trials. A summary of the results, including both direct and indirect comparisons of treatment effects, may help to clarify the above uncertainty. |
X Demographics
The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 6 | 33% |
| Mexico | 1 | 6% |
| Venezuela, Bolivarian Republic of | 1 | 6% |
| Ecuador | 1 | 6% |
| Canada | 1 | 6% |
| France | 1 | 6% |
| Unknown | 7 | 39% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 14 | 78% |
| Practitioners (doctors, other healthcare professionals) | 3 | 17% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 398 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 4 | 1% |
| Spain | 3 | <1% |
| Portugal | 2 | <1% |
| United States | 2 | <1% |
| Italy | 1 | <1% |
| Canada | 1 | <1% |
| Netherlands | 1 | <1% |
| Argentina | 1 | <1% |
| United Kingdom | 1 | <1% |
| Other | 0 | 0% |
| Unknown | 382 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 64 | 16% |
| Student > Master | 48 | 12% |
| Other | 42 | 11% |
| Student > Ph. D. Student | 39 | 10% |
| Student > Bachelor | 36 | 9% |
| Other | 73 | 18% |
| Unknown | 96 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 149 | 37% |
| Agricultural and Biological Sciences | 20 | 5% |
| Neuroscience | 20 | 5% |
| Nursing and Health Professions | 18 | 5% |
| Psychology | 17 | 4% |
| Other | 70 | 18% |
| Unknown | 104 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 32. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 February 2020.
All research outputs
#1,263,742
of 25,595,500 outputs
Outputs from Cochrane database of systematic reviews
#2,667
of 13,156 outputs
Outputs of similar age
#10,197
of 210,567 outputs
Outputs of similar age from Cochrane database of systematic reviews
#55
of 300 outputs
Altmetric has tracked 25,595,500 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,156 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.8. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,567 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 300 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.